ZNTL
Zentalis Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 to Feb 10 ▼ 5 days of insider sells: $134.7K by 3 insiders, avg $2.43
- May 21 ▲ Zentalis announced positive Phase 1b data for azenosertib plus pacli…
- Aug 13 Offering: Zentalis Pharmaceuticals Announces Proposed Underwritten P…
- Aug 14 ▲ 1 insider buy $15.2M at $3.50
- Aug 14 ▼ Zentalis Pharmaceuticals priced a public offering of 23,000,000 shar…
- Aug 14 ▼ Zentalis Pharmaceuticals priced an underwritten public offering of 2…
- Aug 14 Offering: Zentalis Pharmaceuticals Announces Pricing of Underwritten…
- Aug 17 Offering: Zentalis Pharmaceuticals Announces Closing of Underwritten…
- Oct 1 Activist stake: Zentalis Pharmaceuticals Announces Inducement Grants Under…
- Oct 18 ▲ Zentalis announced positive overall survival data from an interim an…
- Oct 18 FDA: Zentalis Pharmaceuticals Announces First Overall Survival…
- Nov 10 ▲ Wedbush upgrades
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $15.2M at an average $3.50. 3 insiders sold $134.7K. Price is 54% below their cost.
- InstitutionsMIXED
Q3 2026: 15 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
13 of 17 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.490 → −$0.519 over 90 days. 2 up, 1 down in 30 days.
- Short sellersCOVERING
Short interest −15.9% to 5.04M shares. 3.5 days to cover, ≈5.3% of shares.
- TrendDOWNTREND
36% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $3.5M |
| Qube Research & Technologies Ltd | ADD | $3.1M |
| STATE STREET CORP | ADD | $3.1M |
| JPMORGAN CHASE & CO | DOUBLED | $2.6M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $2.0M |
| FMR LLC | DOUBLED | $1.9M |
| MARSHALL WACE, LLP | TRIM | $1.2M |
| Squarepoint Ops LLC | DOUBLED | $706.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +337%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Wedbush UPGRADE | Outperform |
| Oct 19, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 16, 2026 | William Blair INITIATE | Outperform |
| Jul 23, 2026 | Rodman & Renshaw INITIATE | Buy |
| Jul 17, 2026 | Mizuho INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bruns Ingmar Chief Medical Officer Sep 30, 2026 | AWARD | $21.2K |
WALTERS GROUP 10%+ Owner Aug 14, 2026 | BUY | $15.2M |
Myers Scott Dunseth Director Jun 16, 2026 | AWARD | 57,100 sh |
Skvarka Jan Director Jun 16, 2026 | AWARD | 57,100 sh |
Kariuki Enoch Director Jun 16, 2026 | AWARD | 57,100 sh |
Walker Luke Nathaniel Director Jun 16, 2026 | AWARD | 57,100 sh |
Johnson David Michael Director Jun 16, 2026 | AWARD | 57,100 sh |
Campbell Shannon Director May 26, 2026 | AWARD | 114,200 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.38 | -$0.45–-$0.25 | +10.1% | $0.00 |
| Next Q | -$0.48 | -$0.63–-$0.40 | +22.6% | $133.3K |
| Current FY | -$1.75 | -$1.86–-$1.50 | +13.0% | $0.00 |
| Next FY | -$1.52 | -$1.90–-$1.06 | +16.2% | $1.6M |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 7 press releases · 6 bullish · 2 bearish · 1 mixed · 2 neutral- NEUTRAL SC 13G/ANov 16, 2026
Squadron Capital Management LLC filed an amended Schedule 13G disclosing a 7.3% passive stake in Zentalis Pharmaceuticals as of September 30, 2026, up from a prior 4.1% stake reported by BlackRock. The filing shows Squadron holds 6,927,905 shares, including 100,000 shares underlying exercisable…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 9, 2026
Zentalis reported Q3 2026 net loss of $28.8M ($0.34 per share), narrower than the $0.52 consensus…
The delay of the DENALI Part 2 topline readout from year-end 2026 to 1H 2027 pushes back the key catalyst and any potential FDA submission. The August follow-on offering diluted existing holders by…
- NEUTRAL SC 13G/AOct 27, 2026
BlackRock Inc. filed an amended Schedule 13G disclosing a 4.1% passive stake in Zentalis…
BlackRock's reduction below 5% removes a large passive holder from the 5%+ roster, but as a routine portfolio adjustment by a passive asset manager, it does not signal a fundamental view on…
- BULLISH PRESS RELEASEOct 18, 2026
Zentalis announced positive overall survival data from an interim analysis of the DENALI Part 1b…
The ESMO presentation on October 23, 2026 will provide the first public disclosure of full OS data. Positive data could significantly increase the probability of accelerated approval for azenosertib…
All ZNTL filing & press-release reports (18)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 9, 2026
- SC 13G/A reportOct 27, 2026
- PRESS-RELEASE reportOct 18, 2026
- PRESS-RELEASE reportOct 1, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 13, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 21, 2026
- 8-K reportMay 21, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- 8-K reportApr 17, 2026
- 8-K reportApr 9, 2026
- PRESS-RELEASE reportMar 26, 2026